{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:15Z","timestamp":1790286915781,"version":"4.1.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.det.2026.01.009","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T21:01:53Z","timestamp":1771966913000},"page":"281-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["New and Emerging Drug Reactions"],"prefix":"10.1016","volume":"44","author":[{"given":"Emily Y.","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuong V.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.det.2026.01.009_bib1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2017.01.012","article-title":"Adverse reactions to biologic therapy","volume":"37","author":"Patel","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"10.1016\/j.det.2026.01.009_bib2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2026.01.009_bib3","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","article-title":"Adverse side-effects to biological agents","volume":"61","author":"Pichler","year":"2006","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.det.2026.01.009_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.9152","article-title":"Rituximab-induced serum sickness in immunobullous disorders: a case series","volume":"12","author":"Gheisari","year":"2024","journal-title":"Clin Case Rep"},{"issue":"2","key":"10.1016\/j.det.2026.01.009_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jemermed.2006.12.005","article-title":"Repeated infliximab therapy after serum sickness-like reaction in Crohn\u2019s disease","volume":"32","author":"Miheller","year":"2007","journal-title":"J Emerg Med"},{"key":"10.1016\/j.det.2026.01.009_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdcr.2024.11.013","article-title":"Dupilumab-induced serum sickness-like reaction in a pediatric patient","volume":"56","author":"Rahman","year":"2025","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.det.2026.01.009_bib7","series-title":"Serum sickness (Die Serumkrankheit)","author":"von Pirquet","year":"1905"},{"issue":"3","key":"10.1016\/j.det.2026.01.009_bib8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0190-9622(85)70182-X","article-title":"Cutaneous manifestations of serum sickness in patients receiving antithymocyte globulin","volume":"13","author":"Bielory","year":"1985","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2026.01.009_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/cup.12863","article-title":"Serum sickness-like drug reaction: two cases with a neutrophilic urticarial pattern","volume":"44","author":"Nguyen","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"3","key":"10.1016\/j.det.2026.01.009_bib10","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.jaad.2011.02.037","article-title":"Serum sickness-like reaction: histopathology and case report","volume":"65","author":"Tolpinrud","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2026.01.009_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cia2.12033","article-title":"Atopic dermatitis as Th2 disease revisited","volume":"1","author":"Tokura","year":"2018","journal-title":"Journal of Cutaneous Immunology and Allergy"},{"issue":"5625","key":"10.1016\/j.det.2026.01.009_bib12","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1126\/science.1085458","article-title":"Interleukin-4 and interleukin-13 signaling connections maps","volume":"300","author":"Ann","year":"2003","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.det.2026.01.009_bib16","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/jamadermatol.2019.0109","article-title":"Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab","volume":"155","author":"Gefei Alex Zhu","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2026.01.009_bib17","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","article-title":"Facial and neck erythema associated with dupilumab treatment: a systematic review","volume":"84","author":"Jo","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2026.01.009_bib18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.18730","article-title":"Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series","volume":"183","author":"de Wijs","year":"2020","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.det.2026.01.009_bib19","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jdcr.2019.07.020","article-title":"Dupilumab facial redness: positive effect of itraconazole","volume":"5","author":"de Beer","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.det.2026.01.009_bib20","article-title":"Psoriasis appearing after dupilumab therapy in atopic dermatitis: a case report","volume":"8","author":"Kim","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2258240","article-title":"Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis","volume":"34","author":"Balakirski","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.det.2026.01.009_bib22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1159\/000530608","article-title":"Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review","volume":"239","author":"Su","year":"2023","journal-title":"Dermatology"},{"issue":"7","key":"10.1016\/j.det.2026.01.009_bib23","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jdcr.2018.05.014","article-title":"Erythrodermic presentation of psoriasis in a patient treated with dupilumab","volume":"4","author":"Tracey","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.det.2026.01.009_bib24","article-title":"Dupilumab-induced scalp psoriasis in a patient with prurigo nodularis: a case report","volume":"15","author":"Al Hawsawi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.det.2026.01.009_bib25","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2147\/CCID.S420904","article-title":"Pustular psoriasis in a patient treated with dupilumab for atopic dermatitis: a case report","volume":"16","author":"Liu","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"10.1016\/j.det.2026.01.009_bib26","first-page":"e161","article-title":"Keloid lesions show increased IL-4\/IL-13 signaling and respond to Th2-targeting dupilumab therapy","volume":"34","author":"Diaz KT","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2026.01.009_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdcr.2021.08.018","article-title":"A case of paradoxical fibrosis and development of morphea in a patient on dupilumab","volume":"17","author":"Kassamali","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.det.2026.01.009_bib28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/pde.15200","article-title":"Morphea after initiation of dupilumab in two pediatric atopic dermatitis patients","volume":"40","author":"Wang","year":"2023","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients","volume":"83","author":"Espinosa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2026.01.009_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2025.02.099","article-title":"Considerations on the potential link between dupilumab and cutaneous T-cell lymphoma in atopic dermatitis","author":"Jin","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2026.01.009_bib31","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jaad.2024.10.119","article-title":"Cutaneous T cell lymphoma arising in patients treated with dupilumab: a case series of 18 patients","volume":"92","author":"Accetta","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2026.01.009_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2025.05.681","article-title":"Diagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for atopic dermatitis: a retrospective cohort study from a single tertiary cancer center","author":"Liao","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.det.2026.01.009_bib33","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jamadermatol.2023.3849","article-title":"Dupilumab-associated lymphoid reactions in patients with atopic dermatitis","volume":"159","author":"Boesjes","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2026.01.009_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/2152656720927703","article-title":"Something to sweat about: two cases of dupilumab-induced hyperhidrosis and bromhidrosis","volume":"11","author":"Rowane","year":"2020","journal-title":"Allergy Rhinol (Providence)"},{"issue":"7","key":"10.1016\/j.det.2026.01.009_bib35","article-title":"Generalized granuloma annulare associated with dupilumab therapy","volume":"14","author":"Phelps-Polirer","year":"2022","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.det.2026.01.009_bib36","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.alit.2022.02.006","article-title":"Development of alopecia areata-like reactions in a patient treated with dupilumab","volume":"71","author":"Yamane","year":"2022","journal-title":"Allergol Int"},{"key":"10.1016\/j.det.2026.01.009_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jdcr.2021.11.007","article-title":"Dupilumab-induced erythema nodosum","volume":"19","author":"Mustin","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.det.2026.01.009_bib38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdcr.2021.12.009","article-title":"Pyoderma gangrenosum developing in a patient treated with dupilumab","volume":"20","author":"Nasseh","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.det.2026.01.009_bib39","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.12788\/cutis.0798","article-title":"Dupilumab-associated Sweet syndrome","volume":"111","author":"Fernandez","year":"2023","journal-title":"Cutis"},{"key":"10.1016\/j.det.2026.01.009_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdcr.2023.08.048","article-title":"A case of leukocytoclastic vasculitis in a patient on dupilumab","volume":"42","author":"Bach","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.det.2026.01.009_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2022.12.013","article-title":"Lichenoid-granulomatous drug reactions to dupilumab: a report of 2 cases","volume":"33","author":"Rehan","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.det.2026.01.009_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2023.01.001","article-title":"Dupilumab-induced pityriasis rosea","volume":"33","author":"Zabel","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.det.2026.01.009_bib43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdcr.2024.04.023","article-title":"Severe cutaneous reaction with initiation of dupilumab for atopic dermatitis and prurigo nodularis: an unusual adverse effect","volume":"49","author":"Lavin","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib44","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2304027","article-title":"Injection site reactions after dupilumab or tralokinumab for atopic dermatitis","volume":"35","author":"Martora","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.det.2026.01.009_bib45","author":"Foundation"},{"key":"10.1016\/j.det.2026.01.009_bib47","author":"Stewart"},{"issue":"9","key":"10.1016\/j.det.2026.01.009_bib49","article-title":"Exacerbation of atopic dermatitis associated with ustekinumab treatment in crohn's disease","volume":"14","author":"Andres","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib50","first-page":"64","article-title":"A case of eczematous eruption occurring during treatment with risankizumab","volume":"158","author":"DE Luca","year":"2023","journal-title":"Ital J Dermatol Venerol"},{"issue":"11","key":"10.1016\/j.det.2026.01.009_bib51","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jdcr.2019.09.005","article-title":"Eczematous eruption after guselkumab treatment for psoriasis","volume":"5","author":"Reyn","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"6","key":"10.1016\/j.det.2026.01.009_bib52","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/09546634.2017.1406894","article-title":"A systematic review of ustekinumab in the treatment of atopic dermatitis","volume":"29","author":"Pan","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.det.2026.01.009_bib53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamadermatol.2017.5937","article-title":"Efficacy and safety of Guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial","volume":"154","author":"Terui","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ejhpharm-2018-001849","article-title":"Bullous pemphigoid induced by ustekinumab: a case report","volume":"28","author":"Marin","year":"2021","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.det.2026.01.009_bib55","article-title":"Development of bullous pemphigoid during treatment of psoriasis with ustekinumab: a case report and literature review","volume":"10","author":"Kong","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.det.2026.01.009_bib56","author":"Stewart"},{"key":"10.1016\/j.det.2026.01.009_bib58","author":"Stewart"},{"issue":"6","key":"10.1016\/j.det.2026.01.009_bib59","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/14712598.2020.1727439","article-title":"Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature","volume":"20","author":"Caldarola","year":"2020","journal-title":"Expet Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.det.2026.01.009_bib60","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/cup.13952","article-title":"Drug-induced psoriasiform alopecia associated with interleukin-17 inhibitor therapy","volume":"48","author":"Tan","year":"2021","journal-title":"J Cutan Pathol"},{"issue":"12","key":"10.1016\/j.det.2026.01.009_bib61","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.36849\/JDD.7388","article-title":"A case series of patients with eczematous eruptions following IL-17 inhibitor treatment for psoriasis vulgaris","volume":"22","author":"Yousif","year":"2023","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"10.1016\/j.det.2026.01.009_bib62","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1111\/1756-185X.14667","article-title":"Secukinumab-induced IgA vasculitis in a patient with psoriatic arthritis","volume":"26","author":"Ozince","year":"2023","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib63","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2235040","article-title":"Pyoderma gangrenosum and Behcet\u2019s-like disease induced by secukinumab: a paradoxical drug reaction","volume":"34","author":"Avci","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib64","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2347440","article-title":"Behcet\u2019s-like disease induced by secukinumab in a patient with psoriasis: a case report and literature review","volume":"35","author":"Liu","year":"2024","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib65","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/ijd.ijd_719_24","article-title":"Paradoxical Behcet\u2019s Disease after Ixekizumab: a case report and literature review","volume":"70","author":"Ren","year":"2025","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.det.2026.01.009_bib66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jdcr.2022.09.029","article-title":"A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis","volume":"30","author":"Lee","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib67","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2397477","article-title":"Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis","volume":"35","author":"Chen","year":"2024","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.det.2026.01.009_bib68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2023.04.001","article-title":"Roflumilast enhances the melanogenesis and attenuates oxidative stress-triggered damage in melanocytes","volume":"110","author":"Chen","year":"2023","journal-title":"J Dermatol Sci"},{"issue":"6","key":"10.1016\/j.det.2026.01.009_bib69","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaad.2016.06.042","article-title":"Appearance of lentigines in psoriasis patients treated with apremilast","volume":"75","author":"Sfecci","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib70","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/ced.13692","article-title":"Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast","volume":"44","author":"Vazquez","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.det.2026.01.009_bib71","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/ced.13852","article-title":"Lentigines within fixed drug eruption: reply to \u2018Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast\u2019","volume":"44","author":"McCarthy","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"18","key":"10.1016\/j.det.2026.01.009_bib72","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-12-1972","article-title":"Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy","volume":"19","author":"Nirschl","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.det.2026.01.009_bib73","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.det.2026.01.009_bib74","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced Melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"issue":"Pt 2","key":"10.1016\/j.det.2026.01.009_bib75","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.det.2026.01.009_bib76","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.3390\/curroncol29040234","article-title":"Cutaneous adverse events associated with immune checkpoint inhibitors: a review article","volume":"29","author":"Chen","year":"2022","journal-title":"Curr Oncol"},{"issue":"16_suppl","key":"10.1016\/j.det.2026.01.009_bib77","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.11057","article-title":"Overlapping and non-overlapping indications for checkpoint inhibitors in the US","volume":"42","author":"Paul","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.det.2026.01.009_bib78","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.det.2026.01.009_bib79","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.det.2026.01.009_bib80","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2026.01.009_bib81","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2026.01.009_bib82","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.det.2026.01.009_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","article-title":"Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials","volume":"119","author":"El Osta","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.det.2026.01.009_bib84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"issue":"2","key":"10.1016\/j.det.2026.01.009_bib85","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"4","key":"10.1016\/j.det.2026.01.009_bib86","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib87","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40801-023-00399-7","article-title":"Immune checkpoint inhibitors and scleroderma: data from the European Pharmacovigilance database","volume":"11","author":"Nicoletti","year":"2024","journal-title":"Drugs Real World Outcomes"},{"issue":"9","key":"10.1016\/j.det.2026.01.009_bib88","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2026.01.009_bib89","series-title":"Cutaneous drug eruptions. Barnhill\u2019s dermatopathology","author":"JL","year":"2020"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib90","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/cup.14145","article-title":"Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy","volume":"49","author":"Seervai","year":"2022","journal-title":"J Cutan Pathol"},{"issue":"2","key":"10.1016\/j.det.2026.01.009_bib91","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.path.2021.01.002","article-title":"Cutaneous toxicities in the setting of immune checkpoint blockade:: the era of oncodermatopathology","volume":"14","author":"Curry","year":"2021","journal-title":"Surg Pathol Clin"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib92","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00403-024-03694-7","article-title":"Eruptive keratoacanthoma secondary to immune checkpoint inhibitors: a narrative review","volume":"317","author":"Mager","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.det.2026.01.009_bib93","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jdin.2023.11.013","article-title":"Checkpoint inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression level","volume":"15","author":"Meier-Schiesser","year":"2024","journal-title":"JAAD Int"},{"issue":"10","key":"10.1016\/j.det.2026.01.009_bib94","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/cup.13739","article-title":"Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: a diagnostic pitfall for superficially invasive squamous cell carcinoma","volume":"47","author":"Marques-Piubelli","year":"2020","journal-title":"J Cutan Pathol"},{"issue":"11","key":"10.1016\/j.det.2026.01.009_bib95","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/cup.13536","article-title":"Lichenoid dermatitis from immune checkpoint inhibitor therapy: an immune-related adverse event with mycosis-fungoides-like morphologic and molecular features","volume":"46","author":"Tetzlaff","year":"2019","journal-title":"J Cutan Pathol"},{"issue":"10","key":"10.1016\/j.det.2026.01.009_bib96","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/cup.13013","article-title":"PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-report of 4 cases","volume":"44","author":"Chou","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.det.2026.01.009_bib97","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdcr.2021.02.012","article-title":"Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma","volume":"10","author":"McNally","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"11","key":"10.1016\/j.det.2026.01.009_bib98","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/cup.14299","article-title":"Lichen-planus-pemphigoides-like reaction to PD-1 checkpoint blockade","volume":"49","author":"Wat","year":"2022","journal-title":"J Cutan Pathol"},{"issue":"8","key":"10.1016\/j.det.2026.01.009_bib99","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol"},{"issue":"7","key":"10.1016\/j.det.2026.01.009_bib100","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/cup.14442","article-title":"Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4\/complement-induced innate immune response and increased density of T(H) 1 T-cells","volume":"50","author":"Marques-Piubelli","year":"2023","journal-title":"J Cutan Pathol"},{"issue":"3","key":"10.1016\/j.det.2026.01.009_bib101","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jdcr.2017.09.028","article-title":"Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma","volume":"4","author":"Griffin","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.det.2026.01.009_bib102","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"4","key":"10.1016\/j.det.2026.01.009_bib103","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/DAD.0000000000001527","article-title":"Pembrolizumab-induced stevens-johnson Syndrome\/Toxic epidermal necrolysis in a patient with metastatic cervical squamous cell carcinoma: a case report","volume":"42","author":"Robinson","year":"2020","journal-title":"Am J Dermatopathol"},{"issue":"7","key":"10.1016\/j.det.2026.01.009_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15072084","article-title":"Cutaneous adverse reactions of immunotherapy in patients with advanced melanoma","volume":"15","author":"Nikolaou","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients","volume":"6","author":"Tetzlaff","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.det.2026.01.009_bib106","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/cup.13044","article-title":"Erythema nodosum-like panniculitis mimicking disease recurrence: a novel toxicity from immune checkpoint blockade therapy-Report of 2 patients","volume":"44","author":"Tetzlaff","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"10","key":"10.1016\/j.det.2026.01.009_bib107","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"issue":"Number 16_suppl","key":"10.1016\/j.det.2026.01.009_bib108","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.6044","article-title":"An open-label, single-center phase II trial of cadonilimab (an anti-PD-1\/CTLA-4 bispecific antibody) in combination with platinum-based dual-drug neoadjuvant chemotherapy for locally advanced, resectable head and neck squamous cell carcinoma","volume":"42","author":"Cao","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.det.2026.01.009_bib109","article-title":"KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: a multicenter phase 2 trial","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell Rep Med"},{"issue":"9","key":"10.1016\/j.det.2026.01.009_bib110","article-title":"Development and preliminary clinical activity of PD-1-Guided CTLA-4 blocking bispecific DART molecule","volume":"1","author":"Berezhnoy","year":"2020","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib111","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-023-01445-1","article-title":"First-in-human phase I\/Ib study of QL1706 (PSB205), a bifunctional PD1\/CTLA4 dual blocker, in patients with advanced solid tumors","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.det.2026.01.009_bib112","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-024-01644-4","article-title":"The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia\/Ib study","volume":"17","author":"Ruan","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"16_suppl","key":"10.1016\/j.det.2026.01.009_bib113","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.2527","article-title":"SI-B003 (PD-1\/CTLA-4) in patients with advanced solid tumors: a phase I study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.det.2026.01.009_bib114","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.2022.40.16_suppl.107","article-title":"Safety and clinical activity of MEDI5752, a PD-1\/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): preliminary results from an FTIH trial","volume":"40","author":"Albiges","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.det.2026.01.009_bib115","article-title":"Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors","volume":"9doi","author":"Shum","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.det.2026.01.009_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1155778","article-title":"Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy","volume":"14","author":"Farhangnia","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.det.2026.01.009_bib117","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/2159-8290.CD-21-0257","article-title":"Bispecific antibodies to PD-1 and CTLA4: doubling Down on T cells to decouple efficacy from toxicity","volume":"11","author":"Burton","year":"2021","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.det.2026.01.009_bib118","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e82","article-title":"Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer","volume":"35","author":"Bose","year":"2024","journal-title":"J Gynecol Oncol"},{"issue":"suppl_2","key":"10.1016\/j.det.2026.01.009_bib119","article-title":"MEDI5752 (volrustomig), a novel PD-1\/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)","volume":"34","author":"Voss BG","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.det.2026.01.009_bib120","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","article-title":"Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or sezary syndrome","volume":"157","author":"Hirotsu","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.det.2026.01.009_bib121","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/PAS.0000000000001587","article-title":"Histopathologic characterization of mogamulizumab-associated rash","volume":"44","author":"Wang","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.det.2026.01.009_bib122","doi-asserted-by":"crossref","DOI":"10.1111\/ddg.15773","article-title":"Novel and recurrent histopathologic patterns of mogamulizumab-associated rash: diagnostic implications and insights for accurate diagnosis","author":"Mitteldorf","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"issue":"11","key":"10.1016\/j.det.2026.01.009_bib123","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/cup.14689","article-title":"Enfortumab vedotin-induced cutaneous eruption: ring mitotic figures as a distinctive histopathologic feature","volume":"51","author":"Sport","year":"2024","journal-title":"J Cutan Pathol"},{"issue":"9","key":"10.1016\/j.det.2026.01.009_bib124","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/PAS.0000000000002268","article-title":"Histopathologic and clinical characterization of Brentuximab Vedotin-associated rash","volume":"48","author":"Narala","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.det.2026.01.009_bib125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/DAD.0000000000002911","article-title":"Histopathologic comparison among drug eruptions induced by Enfortumab Vedotin, Brentuximab Vedotin, and taxanes","volume":"47","author":"Iwahashi","year":"2025","journal-title":"Am J Dermatopathol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863526000094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863526000094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:37:11Z","timestamp":1775515031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863526000094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":119,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0733863526000094"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2026.01.009","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New and Emerging Drug Reactions","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2026.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}